Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants
By Adriano Marchese
Vertex Pharmaceuticals said Friday that its treatment for cystic fibrosis was given a positive opinion by European Union regulators to treat infants with specific mutations of the gene.
The pharmaceutical company said that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for the label expansion of the drug ivacaftor, also known as Kalydeco.
The approval is to expand the treatment of infants with cystic fibrosis between the ages of one to four months who have certain specific mutations of the cystic fibrosis transmembrane conductance regulator gene.
Kalydeco aims to treat the underlying cause of cystic fibrosis, a life-shortening genetic disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract.
In the EU, the treatment is already approved to treat the disorder in patients aged four months and older.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 23, 2024 07:59 ET (12:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software